Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Bryan W Miller; Jennifer P Morton; Mark Pinese; Grazia Saturno; Nigel B Jamieson; Ewan McGhee; Paul Timpson; Joshua Leach; Lynn McGarry; Emma Shanks; Peter Bailey; David Chang; Karin Oien; Saadia Karim; Amy Au; Colin Steele; Christopher Ross Carter; Colin McKay; Kurt Anderson; Thomas R Jeffry Evans; Richard Marais; Caroline Springer; Andrew Biankin; Janine T Erler; Owen J Sansom

Journal article

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Bryan W Miller, Jennifer P Morton, Mark Pinese, Grazia Saturno, Nigel B Jamieson, Ewan McGhee, Paul Timpson, Joshua Leach, Lynn McGarry, Emma Shanks, Peter Bailey, David Chang, Karin Oien, Saadia Karim, Amy Au, Colin Steele, Christopher Ross Carter, Colin McKay, Kurt Anderson, Thomas R Jeffry Evans Show all

EMBO Molecular Medicine | WILEY | Published : 2015

DOI: 10.15252/emmm.201404827

University of Melbourne Researchers

Colette McKay Author Medical Bionics Department

Grants

Awarded by Academy of Medical Sciences (AMS)

Awarded by Cancer Research UK

Awarded by Novo Nordisk Fonden

Awarded by Versus Arthritis

Awarded by Wellcome Trust

Funding Acknowledgements

The authors would like to thank the Cancer Research UK Beatson Institute Biological Services, Colin Nixon and the Histology Service, and Gabriela Kalna for assistance with data analysis; Tashinga Bapiro, Frances Richards and Duncan Jodrell for assessment of gemcitabine pharmacokinetics; and Jane Hair for curation of the National Health Service Greater Glasgow and Clyde biorepository. JTE is funded by the Novo Nordisk Foundation (Hallas Moller Stipend). This work was funded by Cancer Research UK and the Pancreatic Cancer Research Fund.